Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (15570)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 28, 2018 (publication date) through Dec 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Hilmi M, Bartholin L, Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? World J Gastroenterol 2018; 24(20): 2137-2151 [PMID: 29853732 DOI: 10.3748/wjg.v24.i20.2137] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v24/i20/2137.htm |
| Number | Citing Articles |
| 1 |
Martino Maddalena, Giuseppe Mallel, Nishanth Belugali Nataraj, Michal Shreberk-Shaked, Ori Hassin, Saptaparna Mukherjee, Sharathchandra Arandkar, Ron Rotkopf, Abby Kapsack, Giuseppina Lambiase, Bianca Pellegrino, Eyal Ben-Isaac, Ofra Golani, Yoseph Addadi, Emma Hajaj, Raya Eilam, Ravid Straussman, Yosef Yarden, Michal Lotem, Moshe Oren.
TP53
missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment
. Proceedings of the National Academy of Sciences 2021; 118(23) doi: 10.1073/pnas.2025631118
|
| 2 |
Saber Amin, Michael Baine, Jane Meza, Chi Lin. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07016-8
|
| 3 |
Sijia Tang, Lei Shi, Breona T. Luker, Channen Mickler, Bhavana Suresh, Gregory B. Lesinski, Daping Fan, Yuan Liu, Ming Luo. Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model. Virology Journal 2022; 19(1) doi: 10.1186/s12985-022-01757-7
|
| 4 |
Erik B. Faber, Harris B. Krause, Khalid Amin, Philip Walker, Peter J. Hosein, Anthony F. Shields, Heinz-Josef Lenz, Ajay Prakash, Sanjay Goel, Matthew Oberley, Giuseppe Malleo, Claudio Luchini, Justin Hwang, Vaia Florou, Ignacio Garrido‐Laguna, Emil Lou. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets. JCO Precision Oncology 2024; (8) doi: 10.1200/PO.23.00595
|
| 5 |
Xiaochuan Hu, Guoyi Ke, Sophia R.-J. Jang. Modeling Pancreatic Cancer Dynamics with Immunotherapy. Bulletin of Mathematical Biology 2019; 81(6): 1885 doi: 10.1007/s11538-019-00591-3
|
| 6 |
Andrew J. Gunderson, Venkatesh Rajamanickam, Cynthia Bui, Brady Bernard, Joanna Pucilowska, Carmen Ballesteros-Merino, Mark Schmidt, Kayla McCarty, Michaela Philips, Brian Piening, Christopher Dubay, Terry Medler, Phillipa Newell, Paul Hansen, Eric Tran, Ephraim Tang, Carlo Bifulco, Marka Crittenden, Michael Gough, Kristina H. Young. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer. OncoImmunology 2021; 10(1) doi: 10.1080/2162402X.2021.1900635
|
| 7 |
Zhengting Jiang, Wenjie Zhang, Zhilin Zhang, Gengyu Sha, Daorong Wang, Dong Tang. Intratumoral microbiota: A new force in diagnosing and treating pancreatic cancer. Cancer Letters 2023; 554: 216031 doi: 10.1016/j.canlet.2022.216031
|
| 8 |
Donatella Delle Cave, Riccardo Rizzo, Bruno Sainz, Giuseppe Gigli, Loretta L. del Mercato, Enza Lonardo. The Revolutionary Roads to Study Cell–Cell Interactions in 3D In Vitro Pancreatic Cancer Models. Cancers 2021; 13(4): 930 doi: 10.3390/cancers13040930
|
| 9 |
Hsuan‐Chen Liu, Daniel Davila Gonzalez, Dixita Ishani Viswanath, Robin Shae Vander Pol, Shani Zakiya Saunders, Nicola Di Trani, Yitian Xu, Junjun Zheng, Shu‐Hsia Chen, Corrine Ying Xuan Chua, Alessandro Grattoni. Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Advanced Science 2023; 10(9) doi: 10.1002/advs.202206873
|
| 10 |
Amalia Azzariti, Rosa Maria Iacobazzi, Roberta Di Fonte, Letizia Porcelli, Roberto Gristina, Pietro Favia, Francesco Fracassi, Ilaria Trizio, Nicola Silvestris, Gabriella Guida, Stefania Tommasi, Eloisa Sardella. Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-40637-z
|
| 11 |
Shivani Malik, Jill M. Westcott, Rolf A. Brekken, Francis J. Burrows. CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target. Cancers 2021; 14(1): 86 doi: 10.3390/cancers14010086
|
| 12 |
Michael Guenther, Vivien Veninga, Joerg Kumbrink, Michael Haas, C. Benedikt Westphalen, Stephan Kruger, Volker Heinemann, Thomas Kirchner, Stefan Boeck, Andreas Jung, Steffen Ormanns. POLE gene hotspot mutations in advanced pancreatic cancer. Journal of Cancer Research and Clinical Oncology 2018; 144(11): 2161 doi: 10.1007/s00432-018-2746-x
|
| 13 |
Mark R Sullivan, Laura V Danai, Caroline A Lewis, Sze Ham Chan, Dan Y Gui, Tenzin Kunchok, Emily A Dennstedt, Matthew G Vander Heiden, Alexander Muir. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. eLife 2019; 8 doi: 10.7554/eLife.44235
|
| 14 |
Saber Amin, Chi Lin. Immunotherapy Plus Chemoradiation Improves Overall Survival in Stage IV Esophageal Cancer: A Cohort Study. Gastro Hep Advances 2024; 3(3): 302 doi: 10.1016/j.gastha.2023.12.004
|
| 15 |
Jaroslaw Daniluk, Urszula Daniluk, Pawel Rogalski, Andrzej Dabrowski, Agnieszka Swidnicka-Siergiejko. Microbiome—Friend or Foe of Pancreatic Cancer?. Journal of Clinical Medicine 2021; 10(23): 5624 doi: 10.3390/jcm10235624
|
| 16 |
Chin-King Looi, Felicia Fei-Lei Chung, Chee-Onn Leong, Shew-Fung Wong, Rozita Rosli, Chun-Wai Mai. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. Journal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1153-8
|
| 17 |
Mengjiao Fan, Yue Ma, Guochao Deng, Haiyan Si, Ru Jia, Zhikuan Wang, Guanghai Dai. A real-world analysis of second-line treatment option, Gemcitabine plus Anlotinib and anti-PD1, in advanced pancreatic cancer. Pancreatology 2024; doi: 10.1016/j.pan.2024.03.017
|
| 18 |
Pascal Hammel, Carole Vitellius, Émeric Boisteau, Mathilde Wisniewski, Elise Colle, Marc Hilmi, Christelle Dengremont, Sandra Granier, Anthony Turpin, Louis de Mestier, Cindy Neuzillet. Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. Therapeutic Advances in Medical Oncology 2020; 12 doi: 10.1177/1758835920937949
|
| 19 |
Rami Alzhrani, Hashem O. Alsaab, Kushal Vanamala, Ketki Bhise, Katyayani Tatiparti, Ayatakshi Barari, Samaresh Sau, Arun K. Iyer. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Advanced Therapeutics 2021; 4(6) doi: 10.1002/adtp.202000262
|
| 20 |
Roberto Salvia, Fabio Casciani, Elisabetta Sereni, Claudio Bassi. Pancreatic cancer – What's next?. La Presse Médicale 2019; 48(3): e187 doi: 10.1016/j.lpm.2019.02.031
|
| 21 |
Roland Andersson, Carlos-Filipe Pereira, Monika Bauden, Daniel Ansari. Is Immunotherapy the Holy Grail for Pancreatic Cancer?. Immunotherapy 2019; 11(17): 1435 doi: 10.2217/imt-2019-0164
|
| 22 |
Cindy Neuzillet, Rémy Nicolle, Jérôme Raffenne, Annemilaï Tijeras‐Raballand, Alexia Brunel, Lucile Astorgues‐Xerri, Sophie Vacher, Floriane Arbateraz, Marjorie Fanjul, Marc Hilmi, Rémi Samain, Christophe Klein, Aurélie Perraud, Vinciane Rebours, Muriel Mathonnet, Ivan Bièche, Hemant Kocher, Jérôme Cros, Corinne Bousquet. Periostin‐ and podoplanin‐positive cancer‐associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma. The Journal of Pathology 2022; 258(4): 408 doi: 10.1002/path.6011
|
| 23 |
Marie Muller, Vincent Haghnejad, Marion Schaefer, Guillaume Gauchotte, Bénédicte Caron, Laurent Peyrin-Biroulet, Jean-Pierre Bronowicki, Cindy Neuzillet, Anthony Lopez. The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges. Cancers 2022; 14(4): 995 doi: 10.3390/cancers14040995
|
| 24 |
Jinthe Van Loenhout, Tal Flieswasser, Laurie Freire Boullosa, Jorrit De Waele, Jonas Van Audenaerde, Elly Marcq, Julie Jacobs, Abraham Lin, Eva Lion, Heleen Dewitte, Marc Peeters, Sylvia Dewilde, Filip Lardon, Annemie Bogaerts, Christophe Deben, Evelien Smits. Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. Cancers 2019; 11(10): 1597 doi: 10.3390/cancers11101597
|
| 25 |
Tianpeng Zhang, Zongting Gu, Ran Ni, Xiao Wang, Qitao Jiang, Ran Tao. An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma. Frontiers in Bioscience-Landmark 2023; 28(12) doi: 10.31083/j.fbl2812361
|
| 26 |
Marc Hilmi, Angélique Vienot, Benoît Rousseau, Cindy Neuzillet. Immune Therapy for Liver Cancers. Cancers 2019; 12(1): 77 doi: 10.3390/cancers12010077
|
| 27 |
Daoan Cheng, Jing Hu, Xiaoyu Wu, Banglu Wang, Rui Chen, Weiqing Zhao, Cheng Fang, Mei Ji. PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1281545
|
| 28 |
Jonathan J. Hue, Katherine Bingmer, Kavin Sugumar, Sarah C. Markt, Luke D. Rothermel, Jeffrey M. Hardacre, John B. Ammori, Jordan M. Winter, Lee M. Ocuin. Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. Journal of Pancreatic Cancer 2021; 7(1): 31 doi: 10.1089/pancan.2021.0003
|
| 29 |
Claudia C. Preston, Randolph S. Faustino. Nuclear Envelope Regulation of Oncogenic Processes: Roles in Pancreatic Cancer. Epigenomes 2018; 2(3): 15 doi: 10.3390/epigenomes2030015
|
| 30 |
Glancis Luzeena Raja Arul, Merih D. Toruner, Robert A. Gatenby, Ryan M. Carr. Ecoevolutionary biology of pancreatic ductal adenocarcinoma. Pancreatology 2022; 22(6): 730 doi: 10.1016/j.pan.2022.06.005
|
| 31 |
Ghazaleh Pourali, Nima Zafari, Mahla Velayati, Shima Mehrabadi, Mina Maftooh, Seyed Mahdi Hassanian, Majid Ghayour Mobarhan, Gordon A. Ferns, Amir Avan, Majid Khazaei. Therapeutic Potential of Targeting Transforming Growth Factor-beta
(TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer. Current Drug Targets 2023; 24(17): 1335 doi: 10.2174/0113894501264450231129042256
|
| 32 |
Yi Huang, Ping Gong, Li Su, Mei Zhang. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-47223-4
|
| 33 |
Nicholas Osborne, Rebecca Sundseth, Julian Burks, Hong Cao, Xunxian Liu, Alexander H. Kroemer, Lynda Sutton, Allen Cato, Jill P. Smith. Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment. Cancer Immunology, Immunotherapy 2019; 68(10): 1635 doi: 10.1007/s00262-019-02398-6
|
| 34 |
L.C. Cutmore, N.F. Brown, D. Raj, S. Chauduri, P. Wang, J. Maher, Y. Wang, N.R. Lemoine, J.F. Marshall. Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma. Pancreatology 2020; 20(3): 394 doi: 10.1016/j.pan.2020.02.006
|
| 35 |
Saber Amin, Michael Baine, Jane Meza, Morshed Alam, Chi Lin. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database. Radiation Oncology 2020; 15(1) doi: 10.1186/s13014-020-01569-5
|
| 36 |
Marc Hilmi, Matthieu Delaye, Milena Muzzolini, Rémy Nicolle, Jérôme Cros, Pascal Hammel, Victoire Cardot-Ruffino, Cindy Neuzillet. The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy. The Lancet Gastroenterology & Hepatology 2023; 8(12): 1129 doi: 10.1016/S2468-1253(23)00207-8
|
| 37 |
Alexandros Bokas, Pavlos Papakotoulas, Panagiotis Sarantis, Adriana Papadimitropoulou, Athanasios G Papavassiliou, Michalis V Karamouzis. Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas. Cancers 2020; 12(2): 432 doi: 10.3390/cancers12020432
|
| 38 |
Purushottam Lamichhane, Rahul Deshmukh, Julie Brown, Silvia Jakubski, Priyanka Parajuli, Todd Nolan, Dewan Raja, Mary Badawy, Thomas Yoon, Mark Zmiyiwsky, Narottam Lamichhane. Novel Delivery Systems for Checkpoint Inhibitors. Medicines 2019; 6(3): 74 doi: 10.3390/medicines6030074
|
| 39 |
S. Ormanns. Personalisierte Krebsmedizin. Der Pathologe 2018; 39(S2): 221 doi: 10.1007/s00292-018-0539-2
|
| 40 |
Jia Wu, Jianting Cai. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer. Digestive Diseases and Sciences 2021; 66(2): 359 doi: 10.1007/s10620-020-06183-9
|
| 41 |
Sara De Dosso, Alexander R. Siebenhüner, Thomas Winder, Alexander Meisel, Ralph Fritsch, Christoforos Astaras, Petr Szturz, Markus Borner. Treatment landscape of metastatic pancreatic cancer. Cancer Treatment Reviews 2021; 96: 102180 doi: 10.1016/j.ctrv.2021.102180
|
| 42 |
Luisa Barrueto, Francheska Caminero, Lindsay Cash, Courtney Makris, Purushottam Lamichhane, Rahul R. Deshmukh. Resistance to Checkpoint Inhibition in Cancer Immunotherapy. Translational Oncology 2020; 13(3): 100738 doi: 10.1016/j.tranon.2019.12.010
|
| 43 |
Haonan Liu, Di Pan, Zhiyuan Yao, Hongmei Wang, Yuqi Li, Xiaobing Qin, Pengfei Qu, Juanjuan Tang, Zhengxiang Han. Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer. International Immunopharmacology 2024; 139: 112635 doi: 10.1016/j.intimp.2024.112635
|
| 44 |
Elodie Roger, Sylvie Martel, Adrien Bertrand-Chapel, Arnaud Depollier, Nicolas Chuvin, Roxane M. Pommier, Karam Yacoub, Cassandre Caligaris, Victoire Cardot-Ruffino, Véronique Chauvet, Sophie Aires, Kayvan Mohkam, Jean-Yves Mabrut, Mustapha Adham, Tanguy Fenouil, Valérie Hervieu, Laura Broutier, Marie Castets, Cindy Neuzillet, Philippe A. Cassier, Richard Tomasini, Stéphanie Sentis, Laurent Bartholin. Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling. Cell Death & Disease 2019; 10(12) doi: 10.1038/s41419-019-2116-x
|
| 45 |
Nathalia Ferreira, Ajinkya Kulkarni, David Agorku, Teona Midelashvili, Olaf Hardt, Tobias J. Legler, Philipp Ströbel, Lena-Christin Conradi, Frauke Alves, Fernanda Ramos-Gomes, M. Andrea Markus. OrganoIDNet: a deep learning tool for identification of therapeutic effects in PDAC organoid-PBMC co-cultures from time-resolved imaging data. Cellular Oncology 2024; doi: 10.1007/s13402-024-00958-2
|
| 46 |
Jin-Yu Sun, Dengke Zhang, Songquan Wu, Min Xu, Xiao Zhou, Xiao-Jie Lu, Jiansong Ji. Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomarker Research 2020; 8(1) doi: 10.1186/s40364-020-00212-5
|
| 47 |
Leonie Enderle, Karim H. Shalaby, Maryna Gorelik, Alexander Weiss, Levi L. Blazer, Marcin Paduch, Lia Cardarelli, Anthony Kossiakoff, Jarrett J. Adams, Sachdev S. Sidhu. A T cell redirection platform for co-targeting dual antigens on solid tumors. mAbs 2021; 13(1) doi: 10.1080/19420862.2021.1933690
|
| 48 |
E.B. Faber, Y. Baca, J. Xiu, P. Walker, G. Manji, S. Gholami, A. Saeed, A. Prakash, G.P. Botta, D. Sohal, H.J. Lenz, A.F. Shields, C. Nabhan, W. El-Deiry, A. Seeber, V. Chiu, J. Hwang, E. Lou. Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status. ESMO Gastrointestinal Oncology 2024; 4: 100042 doi: 10.1016/j.esmogo.2024.100042
|
| 49 |
Deeksha G Lahori, Pegah Varamini. Nanotechnology-Based Platforms to Improve Immune Checkpoint Blockade Efficacy in Cancer Therapy. Future Oncology 2021; 17(6): 711 doi: 10.2217/fon-2020-0720
|
| 50 |
Tianyi Zhang, Yanxian Ren, Pengfei Yang, Jufang Wang, Heng Zhou. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death & Disease 2022; 13(10) doi: 10.1038/s41419-022-05351-1
|
| 51 |
Rannah Dabiri, Mamoon Ur Rashid, Osama Sherjeel Khan, Sundas Jehanzeb, Mohammad Alomari, Hammad Zafar, Effa Zahid, Asad Ur Rahman, Alvina Karam, Sarfraz Ahmad. Immune Landscape of Pancreatic Cancer Development and Drug Resistance. 2024; : 103 doi: 10.1016/B978-0-443-23523-8.00021-3
|
| 52 |
Nadine Sperb, Miltiadis Tsesmelis, Thomas Wirth. Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences 2020; 21(15): 5486 doi: 10.3390/ijms21155486
|
| 53 |
Yueze Liu, Mengyu Feng, Hao Chen, Gang Yang, Jiangdong Qiu, Fangyu Zhao, Zhe Cao, Wenhao Luo, Jianchun Xiao, Lei You, Lianfang Zheng, Taiping Zhang. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Cancer Letters 2020; 485: 1 doi: 10.1016/j.canlet.2020.05.003
|
| 54 |
Matias Estaras, Antonio Gonzalez. Modulation of cell physiology under hypoxia in pancreatic cancer. World Journal of Gastroenterology 2021; 27(28): 4582-4602 doi: 10.3748/wjg.v27.i28.4582
|
| 55 |
Anthony Turpin, Cindy Neuzillet, Elise Colle, Nelson Dusetti, Rémy Nicolle, Jérôme Cros, Louis de Mestier, Jean-Baptiste Bachet, Pascal Hammel. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Therapeutic Advances in Medical Oncology 2022; 14 doi: 10.1177/17588359221118019
|
| 56 |
J. Fréderique de Graaf, Marco Huberts, Daphne Groeneveld, Stefan van Nieuwkoop, Casper H.J. van Eijck, Ron A.M. Fouchier, Bernadette G. van den Hoogen. Comparison between intratumoral and intravenously administered oncolytic virus therapy with Newcastle disease virus in a xenograft murine model for pancreatic adenocarcinoma. Heliyon 2022; 8(7): e09915 doi: 10.1016/j.heliyon.2022.e09915
|
| 57 |
Fabienne Maibach, Hassan Sadozai, S. Morteza Seyed Jafari, Robert E. Hunger, Mirjam Schenk. Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.02105
|
| 58 |
Max Piffoux, Erwan Eriau, Philippe A. Cassier. Autophagy as a therapeutic target in pancreatic cancer. British Journal of Cancer 2021; 124(2): 333 doi: 10.1038/s41416-020-01039-5
|
| 59 |
Anna Silvia Wenning, Christoph O. Ryser, Andreas Andreou, Beat Gloor, Martin D. Berger. Neues zur Therapie des Pankreaskarzinoms: Hoffnung am Horizont?. Schweizer Gastroenterologie 2021; 2(4): 138 doi: 10.1007/s43472-021-00054-y
|
| 60 |
Sathish Kumar Mungamuri, Anil Kumar Pasupulati, Vijay Aditya Mavuduru. Exploring Pancreatic Metabolism and Malignancy. 2019; : 215 doi: 10.1007/978-981-32-9393-9_13
|
| 61 |
Kanan Panchal, Rakesh Kumar Sahoo, Umesh Gupta, Akash Chaurasiya. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview. International Immunopharmacology 2021; 95: 107508 doi: 10.1016/j.intimp.2021.107508
|
| 62 |
Davide Melisi, Do-Youn Oh, Antoine Hollebecque, Emiliano Calvo, Anna Varghese, Erkut Borazanci, Teresa Macarulla, Valeria Merz, Camilla Zecchetto, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Leena Gandhi, Shawn T Estrem, Karim A Benhadji, Mark C Lanasa, Emin Avsar, Susan C Guba, Rocio Garcia-Carbonero. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Journal for ImmunoTherapy of Cancer 2021; 9(3): e002068 doi: 10.1136/jitc-2020-002068
|
| 63 |
Abhinav V. Reddy, Colin S. Hill, Shuchi Sehgal, Lei Zheng, Jin He, Daniel A. Laheru, Ana De Jesus-Acosta, Joseph M. Herman, Jeffrey Meyer, Amol K. Narang. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy. Radiation Oncology Journal 2022; 40(2): 111 doi: 10.3857/roj.2021.01060
|
| 64 |
Jiali Du, Jichun Gu, Ji Li. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Bioscience Reports 2020; 40(7) doi: 10.1042/BSR20200401
|
| 65 |
Purushottam Lamichhane, Neha P. Amin, Manuj Agarwal, Narottam Lamichhane. Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?. Medicines 2018; 5(4): 114 doi: 10.3390/medicines5040114
|
| 66 |
Dushyant Singh Dahiya, Asim Kichloo, Jagmeet Singh, Michael Albosta, Manidhar Lekkala. Current Immunotherapy in Gastrointestinal Malignancies a Review. Journal of Investigative Medicine 2021; 69(3): 689 doi: 10.1136/jim-2020-001654
|
| 67 |
Michael F. Coleman, Kristyn A. Liu, Alexander J. Pfeil, Suhas K. Etigunta, Xiaohu Tang, Salvador Fabela, Laura M. Lashinger, Zhengrong Cui, Stephen D. Hursting. β-Hydroxy-β-Methylbutyrate Supplementation Promotes Antitumor Immunity in an Obesity Responsive Mouse Model of Pancreatic Ductal Adenocarcinoma. Cancers 2021; 13(24): 6359 doi: 10.3390/cancers13246359
|
| 68 |
Aline Barhli, Jérôme Cros, Laurent Bartholin, Cindy Neuzillet. Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future. Digestive and Liver Disease 2018; 50(10): 979 doi: 10.1016/j.dld.2018.08.009
|
| 69 |
Chenyang Li, Baoyi Zhang, Evelien Schaafsma, Alexandre Reuben, Linghua Wang, Mary Jo Turk, Jianjun Zhang, Chao Cheng. TimiGP: Inferring cell-cell interactions and prognostic associations in the tumor immune microenvironment through gene pairs. Cell Reports Medicine 2023; 4(7): 101121 doi: 10.1016/j.xcrm.2023.101121
|
| 70 |
Sofie Olsson Hau, Sara Wahlin, Sophie Cervin, Vilgot Falk, Björn Nodin, Jacob Elebro, Jakob Eberhard, Bruce Moran, William M Gallagher, Emelie Karnevi, Karin Jirström. PRR11 unveiled as a top candidate biomarker within the RBM3‐regulated transcriptome in pancreatic cancer. The Journal of Pathology: Clinical Research 2022; 8(1): 65 doi: 10.1002/cjp2.238
|
| 71 |
Qi Zhou, Xufeng Tao, Shilin Xia, Fangyue Guo, Chen Pan, Hong Xiang, Dong Shang. T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00382
|
| 72 |
Annemilaï Tijeras-Raballand, Marc Hilmi, Lucile Astorgues-Xerri, Rémy Nicolle, Ivan Bièche, Cindy Neuzillet. Microbiome and pancreatic ductal adenocarcinoma. Clinics and Research in Hepatology and Gastroenterology 2021; 45(2): 101589 doi: 10.1016/j.clinre.2020.101589
|
| 73 |
Luis Guilherme de Oliveira Silva, Fabian Fellipe Bueno Lemos, Marcel Silva Luz, Samuel Luca Rocha Pinheiro, Mariana dos Santos Calmon, Gabriel Lima Correa Santos, Gabriel Reis Rocha, Fabrício Freire de Melo. New avenues for the treatment of immunotherapy-resistant pancreatic cancer. World Journal of Gastrointestinal Oncology 2024; 16(4): 1134-1153 doi: 10.4251/wjgo.v16.i4.1134
|
| 74 |
Panagiotis Sarantis, Evangelos Koustas, Adriana Papadimitropoulou, Athanasios G Papavassiliou, Michalis V Karamouzis. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World Journal of Gastrointestinal Oncology 2020; 12(2): 173-181 doi: 10.4251/wjgo.v12.i2.173
|
| 75 |
Shailendra K. Gautam, Sushil Kumar, Vi Dam, Dario Ghersi, Maneesh Jain, Surinder K. Batra. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy. Seminars in Immunology 2020; 47: 101391 doi: 10.1016/j.smim.2020.101391
|
| 76 |
Zev A. Wainberg, Howard S. Hochster, Edward J. Kim, Ben George, Aparna Kaylan, E. Gabriela Chiorean, David M. Waterhouse, Martin Guiterrez, Aparna Parikh, Rishi Jain, Daniel Ricardo Carrizosa, Hatem H. Soliman, Thomas Lila, David J. Reiss, Daniel W. Pierce, Rafia Bhore, Sibabrata Banerjee, Larry Lyons, Chrystal U. Louis, Teng Jin Ong, Peter J. O'Dwyer. Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clinical Cancer Research 2020; 26(18): 4814 doi: 10.1158/1078-0432.CCR-20-0099
|
| 77 |
Qian Zhang, Liping Lv, Ping Ma, Yangyang Zhang, Jiang Deng, Yanyu Zhang. Identification of an Autophagy-Related Pair Signature for Predicting Prognoses and Immune Activity in Pancreatic Adenocarcinoma. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.743938
|
| 78 |
Mengni Chen, Shengli Yang, Li Fan, Lu Wu, Renwang Chen, Jian Chang, Jianli Hu. Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden. Pancreas 2019; 48(9): 1232 doi: 10.1097/MPA.0000000000001398
|
| 79 |
Clara S. Mundry, Kirsten C. Eberle, Pankaj K. Singh, Michael A. Hollingsworth, Kamiya Mehla. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor’s arsenal. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2020; 1874(1): 188387 doi: 10.1016/j.bbcan.2020.188387
|
| 80 |
Chenfei Zhou, Jun Zhang. Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. Frontiers of Medicine 2019; 13(1): 12 doi: 10.1007/s11684-019-0685-9
|
| 81 |
Didem Saka, Muazzez Gökalp, Betül Piyade, Nedim Can Cevik, Elif Arik Sever, Derya Unutmaz, Güralp O. Ceyhan, Ihsan Ekin Demir, Hande Asimgil. Mechanisms of T-Cell Exhaustion in Pancreatic Cancer. Cancers 2020; 12(8): 2274 doi: 10.3390/cancers12082274
|
| 82 |
Evelyne Tassone, Michela Muscolini, Nadine van Montfoort, John Hiscott. Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment?. Cytokine & Growth Factor Reviews 2020; 56: 141 doi: 10.1016/j.cytogfr.2020.07.015
|
| 83 |
Daniel C. Osei-Bordom, Nikolaos Serifis, Zachary J. Brown, D. Brock Hewitt, Gbemisola Lawal, Gagandeep Sachdeva, Daniel J. Cloonan, Timothy M. Pawlik. Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies. Surgical Oncology 2022; 43: 101803 doi: 10.1016/j.suronc.2022.101803
|
| 84 |
Xiaoyu Guo, Pan Wang, Yuan Li, Yawei Chang, Xiaobing Wang. Microbiomes in pancreatic cancer can be an accomplice or a weapon. Critical Reviews in Oncology/Hematology 2024; 194: 104262 doi: 10.1016/j.critrevonc.2024.104262
|
| 85 |
Prashant Dogra, Javier R. Ramírez, María J. Peláez, Zhihui Wang, Vittorio Cristini, Gulshan Parasher, Manmeet Rawat. Mathematical Modeling to Address Challenges in Pancreatic Cancer. Current Topics in Medicinal Chemistry 2020; 20(5): 367 doi: 10.2174/1568026620666200101095641
|
| 86 |
Shuping Si, Lei Wang, Hui Cao, Yuhua Xu, Qiang Zhan. Co-deficiency of B7-H3 and B7-H4 identifies high CD8 + T cell infiltration and better prognosis in pancreatic cancer. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09294-w
|
| 87 |
Ana Raquel Bastos, Joana Pereira-Marques, Rui Manuel Ferreira, Ceu Figueiredo. Harnessing the Microbiome to Reduce Pancreatic Cancer Burden. Cancers 2023; 15(9): 2629 doi: 10.3390/cancers15092629
|
| 88 |
Caleb R. Stoltzfus, Ramya Sivakumar, Leo Kunz, Brandy E. Olin Pope, Elena Menietti, Dario Speziale, Roberto Adelfio, Marina Bacac, Sara Colombetti, Mario Perro, Michael Y. Gerner. Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.726492
|
| 89 |
Liwei Cao, Chen Huang, Daniel Cui Zhou, Yingwei Hu, T. Mamie Lih, Sara R. Savage, Karsten Krug, David J. Clark, Michael Schnaubelt, Lijun Chen, Felipe da Veiga Leprevost, Rodrigo Vargas Eguez, Weiming Yang, Jianbo Pan, Bo Wen, Yongchao Dou, Wen Jiang, Yuxing Liao, Zhiao Shi, Nadezhda V. Terekhanova, Song Cao, Rita Jui-Hsien Lu, Yize Li, Ruiyang Liu, Houxiang Zhu, Peter Ronning, Yige Wu, Matthew A. Wyczalkowski, Hariharan Easwaran, Ludmila Danilova, Arvind Singh Mer, Seungyeul Yoo, Joshua M. Wang, Wenke Liu, Benjamin Haibe-Kains, Mathangi Thiagarajan, Scott D. Jewell, Galen Hostetter, Chelsea J. Newton, Qing Kay Li, Michael H. Roehrl, David Fenyö, Pei Wang, Alexey I. Nesvizhskii, D.R. Mani, Gilbert S. Omenn, Emily S. Boja, Mehdi Mesri, Ana I. Robles, Henry Rodriguez, Oliver F. Bathe, Daniel W. Chan, Ralph H. Hruban, Li Ding, Bing Zhang, Hui Zhang, Mitual Amin, Eunkyung An, Christina Ayad, Thomas Bauer, Chet Birger, Michael J. Birrer, Simina M. Boca, William Bocik, Melissa Borucki, Shuang Cai, Steven A. Carr, Sandra Cerda, Huan Chen, Steven Chen, David Chesla, Arul M. Chinnaiyan, Antonio Colaprico, Sandra Cottingham, Magdalena Derejska, Saravana M. Dhanasekaran, Marcin J. Domagalski, Brian J. Druker, Elizabeth Duffy, Maureen A. Dyer, Nathan J. Edwards, Matthew J. Ellis, Jennifer Eschbacher, Alicia Francis, Jesse Francis, Stacey Gabriel, Nikolay Gabrovski, Johanna Gardner, Gad Getz, Michael A. Gillette, Charles A. Goldthwaite, Pamela Grady, Shuai Guo, Pushpa Hariharan, Tara Hiltke, Barbara Hindenach, Katherine A. Hoadley, Jasmine Huang, Corbin D. Jones, Karen A. Ketchum, Christopher R. Kinsinger, Jennifer M. Koziak, Katarzyna Kusnierz, Tao Liu, Jiang Long, David Mallery, Sailaja Mareedu, Ronald Matteotti, Nicollette Maunganidze, Peter B. McGarvey, Parham Minoo, Oxana V. Paklina, Amanda G. Paulovich, Samuel H. Payne, Olga Potapova, Barbara Pruetz, Liqun Qi, Nancy Roche, Karin D. Rodland, Daniel C. Rohrer, Eric E. Schadt, Alexey V. Shabunin, Troy Shelton, Yvonne Shutack, Shilpi Singh, Michael Smith, Richard D. Smith, Lori J. Sokoll, James Suh, Ratna R. Thangudu, Shirley X. Tsang, Ki Sung Um, Dana R. Valley, Negin Vatanian, Wenyi Wang, George D. Wilson, Maciej Wiznerowicz, Zhen Zhang, Grace Zhao. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell 2021; 184(19): 5031 doi: 10.1016/j.cell.2021.08.023
|
| 90 |
Sushmitha Sankarasubramanian, Ulrike Pfohl, Christian R. A. Regenbrecht, Christoph Reinhard, Lena Wedeken. Context Matters—Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.760705
|
| 91 |
Lishan Fang, Shaojing Chen, Hui Gong, Shaohua Xia, Sainan Guan, Nali Quan, Yajie Li, Chao Zeng, Ya Chen, Jianhang Du, Shuguang Liu. Identification of an unfolded protein response-related signature for predicting the prognosis of pancreatic ductal adenocarcinoma. Frontiers in Oncology 2023; 12 doi: 10.3389/fonc.2022.1060508
|
| 92 |
Christopher Montemagno, Shamir Cassim, Jacques Pouyssegur, Alexis Broisat, Gilles Pagès. From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences 2020; 21(11): 4067 doi: 10.3390/ijms21114067
|
| 93 |
Juan J Apiz Saab, Lindsey N Dzierozynski, Patrick B Jonker, Roya AminiTabrizi, Hardik Shah, Rosa Elena Menjivar, Andrew J Scott, Zeribe C Nwosu, Zhou Zhu, Riona N Chen, Moses Oh, Colin Sheehan, Daniel R Wahl, Marina Pasca di Magliano, Costas A Lyssiotis, Kay F Macleod, Christopher R Weber, Alexander Muir. Pancreatic tumors exhibit myeloid-driven amino acid stress and upregulate arginine biosynthesis. eLife 2023; 12 doi: 10.7554/eLife.81289
|
| 94 |
Paloma E. Garcia, Michael K. Scales, Benjamin L. Allen, Marina Pasca di Magliano. Pancreatic Fibroblast Heterogeneity: From Development to Cancer. Cells 2020; 9(11): 2464 doi: 10.3390/cells9112464
|
| 95 |
Dafeng Xu, Yu Wang, Yonghai Chen, Jinfang Zheng. Identification of the molecular subtype and prognostic characteristics of pancreatic cancer based on CD8 + T cell-related genes. Cancer Immunology, Immunotherapy 2023; 72(3): 647 doi: 10.1007/s00262-022-03269-3
|